What results can I expect with TYSABRI?

TYSABRI® (natalizumab) can impact relapsing multiple sclerosis (MS)—an impact you and your doctor may see.

There are 3 ways TYSABRI can impact relapsing MS:

  • Reduces the number of flare-ups per year
  • Slows physical disability progression
  • Impacts the number of new brain lesions and existing lesion activity
  • Flare-up Reduction
  • TYSABRI decreases the number of flare-ups (relapses)

    Consider TYSABRI for treatment of relapsing MS

    In a 2-year study:

    • Out of 627 people taking TYSABRI, 67% were flare-up free vs 41% of 315 people who were not taking treatment (placebo) at 2 years
    • People taking TYSABRI averaged 0.22 flare-ups per year vs 0.67 for those not taking treatment (placebo) at 2 years
  • Slow Physical Disability Progression
  • TYSABRI can slow symptoms from getting worse

    TYSABRI slows worsening physical disability

    Of the 627 people who took TYSABRI® (natalizumab) in a 2-year study:

    • People who were treated with TYSABRI were 42% less likely to develop worsening physical disability sustained for 12 weeks than those not taking treatment (placebo)
    • 29% of people who received no treatment (placebo) had their physical disability worsen, vs 17% of those who were treated with TYSABRI
  • Lesions May Leave Their Mark
  • TYSABRI can impact lesions that show disease activity

    A lesion forms when immune-system cells have wrongly attacked a layer (myelin sheath) of the brain, leaving behind an area of badly damaged or destroyed nerves. When a nerve is damaged or destroyed, the way cells transmit information is drastically affected and can cause major disability.

    Almost everyone taking TYSABRI had no new active lesions that showed disease activity, as seen in a 2-year study:


Learn about infusions... More >>

Open Close


TYSABRI® (natalizumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) to slow the worsening of symptoms common in people with MS and to decrease the number of flare-ups (relapses). TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). When starting and continuing treatment with TYSABRI, it is important to discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk.

Important Safety Information

TYSABRI increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy (PML)—that usually leads to death or severe disability.

Before receiving TYSABRI, it is important to tell your doctor:
TYSABRI can cause serious side effects. If you have any of the symptoms listed below, call your doctor right away:
The most common side effects of TYSABRI are:
These are not all of the possible side effects of TYSABRI. For more information, ask your doctor. To report side effects to FDA, please call 1-800-FDA-1088.

Please see Full Prescribing Information (PDF) including Boxed Warning and Patient Medication Guide (PDF).

This information is not intended to replace discussions with your healthcare provider.